Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia

• Amy K. Keating,
• Nathan Gossai,
• Christine L. Phillips,
• Kelly Maloney,
• Kristen Campbell,
• Andrew Doan,
• Deepa Bhojwani,
• Michael J. Burke,
• Michael R. Verneris

Affiliations

Amy K. Keating

Department of Pediatrics, University of Colorado School of Medicine and The Children's Hospital of Colorado, Aurora, CO; Amy K. Keating, University of Colorado School of Medicine, Department of Pediatrics, Children's Hospital of Colorado, 13123 East 16th Ave, Aurora, CO 80045

Nathan Gossai

Children's Minnesota, Minneapolis, MN

Christine L. Phillips

Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Kelly Maloney

Department of Pediatrics, University of Colorado School of Medicine and The Children's Hospital of Colorado, Aurora, CO

Kristen Campbell

Department of Pediatrics, University of Colorado School of Medicine and The Children's Hospital of Colorado, Aurora, CO

Andrew Doan

Children's Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles, CA

Deepa Bhojwani

Children's Hospital of Wisconsin, Milwaukee, WI

Michael J. Burke

Children's Hospital of Wisconsin, Milwaukee, WI

Michael R. Verneris

Department of Pediatrics, University of Colorado School of Medicine and The Children's Hospital of Colorado, Aurora, CO